Novo’s CEO Ready to Go ‘Very Big’ in Hunt for Obesity Deals

Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a bidding war with Pfizer Inc. late last year.

“We’re in the market for big or small,” Chief Executive Officer Mike Doustdar said in an interview at the JPMorgan Healthcare Conference in San Francisco. “As long as it’s complementary to our own assets, then we can go very big, very big in buying something in, but it has to be worth it and it has to be so much better than whatever we have.”